Geng, Ruishuang
Omar, Akil
Gopal, Suhasini R. http://orcid.org/0000-0002-3525-3222
Chen, Daniel H.-C.
Stepanyan, Ruben
Basch, Martin L.
Dinculescu, Astra
Furness, David N.
Saperstein, David
Hauswirth, William
Lustig, Lawrence R.
Alagramam, Kumar N.
Article History
Received: 21 April 2017
Accepted: 29 September 2017
First Online: 18 October 2017
Competing Interests
: The authors declare the following competing financial interests: The mouse <i>Clrn1</i> cDNA used to generate the transgenic mouse TgAC1 and the human ortholog are protected by a provisional US patent # 62/076,114 and 62/158,846 to K.N.A. WWH and the University of Florida have a financial interest in the use of AAV therapies and own equity in a company (AGTC Inc.) that might, in the future, commercialize some aspects of this work.